The evaluation of the potential role of FGFR/VEGFR pathways in MTC treatment, as an alternative target to conventional drugs targeting RET could be interesting, particularly in patients with MTC negative for RET mutations. Here, KDR is linked to medullary thyroid gland carcinoma.